OncoVerity
OncoVerity is a clinical-stage biopharmaceutical company developing cusatuzumab, a high-affinity anti-CD70 monoclonal antibody licensed from argenx, for elderly newly diagnosed AML patients ineligible for intensive chemotherapy, supported by a proprietary multi-omics bioinformatics platform for patient stratification.
- Company typePrivate
- Founded2023
- HeadquartersAurora, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What OncoVerity does
OncoVerity, Inc. is a clinical-stage biopharmaceutical company focused on advancing cusatuzumab, a high-affinity anti-CD70 monoclonal antibody, for the treatment of acute myeloid leukemia (AML) and other cancers. The company secured exclusive worldwide licensing rights to cusatuzumab from argenx in March 2023 and was incorporated in 2022, operating from Aurora, Colorado within the Fitzsimons Innovation Community. Cusatuzumab targets the CD70 surface protein expressed on various tumors, blocking CD70/CD27 signaling to inhibit leukemia stem cell proliferation while exerting Fc-mediated effector functions including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. The drug has been evaluated in over 100 treated patients with AML across monotherapy and combination studies without dose-limiting toxicities, and is being studied in combination with azacitidine and venetoclax for elderly newly diagnosed AML patients ineligible for intensive chemotherapy through the Elevate, Culminate, and Risk Stratified Phase 2 programs.
The company's underlying technology consists of an advanced bioinformatics platform that applies multi-omics and computational tools to identify novel therapeutic targets and to stratify patient populations most likely to benefit from cusatuzumab combination therapy. OncoVerity conducts multicenter, multinational clinical trials across the US, Europe, and Japan. A collaboration with Verily using the Refinery platform achieved greater than 95% accuracy on complex AML clinical variables in a case study and identified cusatuzumab as a potential drug rescue opportunity for a specific patient subclass. The University of Colorado Anschutz Medical Campus subsequently committed to a multi-year expansion of the Verily Refinery data solution to population-level datasets across cardiovascular disease, neuroscience, and ophthalmology, broadening the platform's applicability beyond oncology.
As a pre-revenue clinical-stage biotech, OncoVerity generates no commercial product revenue and is funded through venture financing. The company has raised approximately $44 million in aggregate (a $30 million Series A in 2022 led by argenx with University License Equity Holdings, plus a $14 million extended Series A in November 2024 from argenx and RefinedScience). Capital is deployed toward Phase 2 clinical development of cusatuzumab, multi-omics platform advancement, and the buildout of commercial-grade operational functions under the leadership of CEO Max Colao and CMO Michael Boyiadzis. Future revenue is expected to be generated through pharmaceutical product sales upon regulatory approval, with distribution planned via hospital pharmacies, specialty pharmacies, and oncology treatment centers.
OncoVerity firmographics
Firmographics- Name
- OncoVerity
- Legal name
- OncoVerity, Inc.
- Website
- https://oncoverity.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OncoVerity is a clinical-stage biopharmaceutical company developing cusatuzumab, a high-affinity anti-CD70 monoclonal antibody licensed from argenx, for elderly newly diagnosed AML patients ineligible for intensive chemotherapy, supported by a proprietary multi-omics bioinformatics platform for patient stratification.
- Ownership category
- akta.pro rank
OncoVerity industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industries
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where OncoVerity is headquartered
LocationHeadquarters
- HQ city
- Aurora
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OncoVerity business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical stage biotech company developing cusatuzumab, an anti-CD70 monoclonal antibody for AML and other cancers. Revenue will be generated through pharmaceutical product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
OncoVerity product offering
Product offeringCore offering
OncoVerity is a clinical-stage biotechnology company developing cusatuzumab, a high-affinity anti-CD70 monoclonal antibody, for the treatment of acute myeloid leukemia (AML) and other cancers. The company applies an advanced multi-omics bioinformatics platform to identify patient subgroups who may benefit from cusatuzumab combination therapy with azacitidine and venetoclax, particularly elderly AML patients ineligible for intensive chemotherapy. Its clinical programs include the Elevate, Culminate, and Risk Stratified Phase 2 studies.
Product overview
OncoVerity is a mission-driven biotech company that applies computational tools and an advanced bioinformatics platform to clinical and biologic data to advance cancer therapies. Their core product is Cusatuzumab, a high-affinity anti-CD70 monoclonal antibody for treating AML and other cancers. The precision medicine platform supports patient stratification to identify subgroups who may benefit from cusatuzumab treatment in combination with azacitidine and venetoclax. The company's clinical programs include Elevate, Culminate, and a Risk Stratified Phase 2 Study.
Differentiator
Problem solved
Functional benefit
Products and services
- Cusatuzumab Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody that targets CD70, a surface protein expressed on various tumors including acute myeloid leukemia (AML). It blocks CD70/CD27 signaling to inhibit leukemia stem cell proliferation and reduces leukemic blast cells, while also exerting direct Fc-mediated effector functions via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. It is being developed for elderly patients with newly diagnosed AML who are not candidates for intensive chemotherapy, in combination with azacitidine and venetoclax.
Quantifiable outcome
- Cusatuzumab has not demonstrated dose limiting toxicities over a range of doses in greater than 100 treated patients with AML.
- +1 more outcomes
Companies that use OncoVerity
Customer profileSegments1 record
Ideal customer profiles2 records
OncoVerity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
OncoVerity partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- argenxcoreOncoVerity secured exclusive worldwide licensing rights to cusatuzumab from argenx. Arjen Lemmen, EVP of Corporate Development & Strategy at argenx, and Petra Van Vlierberghe, VP Head of Global Clinical Operations at argenx, serve on OncoVerity's Board of Directors. The strategic collaboration includes the Janssen partnership for cusatuzumab that argenx previously established.
- UCHealthcoreSteve Hess, CIO of UCHealth, serves on OncoVerity's Board of Directors. UCHealth is a nationally recognized, nonprofit health care system with 12 Colorado hospitals and over 150 clinic locations. The partnership provides clinical infrastructure and collaboration opportunities.
- CU InnovationscoreKimberly Muller, Executive Director of CU Innovations, serves on OncoVerity's Board of Directors. CU Innovations leads innovation for the University of Colorado Anschutz Medical Campus with business development responsibilities including investing, company creation, and strategic industry partnerships in AI and drug development.
- VerilysupportingCollaboration using Verily Refinery platform to transform disparate clinical data into structured, clinically informed formats. In a case study focused on AML, the approach achieved greater than 95% accuracy on complex variables and identified cusatuzumab as a potential drug rescue opportunity for a specific AML patient subclass.
- University of Colorado Anschutz Medical CampuscoreAcademic partner providing clinical infrastructure and single cell multiomics capabilities. Following positive results from AML case study, CU Anschutz has committed to multi-year expansion scaling the data solution to population-level datasets across cardiovascular disease, neuroscience, and ophthalmology.
- RefinedSciencesupportingCollaboration partner in overcoming low-resolution clinical data bottlenecks that prevent effective AI and machine learning applications in healthcare, working with Verily Refinery to transform disparate data into structured formats.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
OncoVerity competitors and assessment
Company assessmentDirect peers
- Aptose Biosciences: Clinical-stage biotech developing tuspetinib and other kinase inhibitors for AML and other hematologic malignancies. Competes head-to-head in the AML combination therapy landscape with OncoVerity.
- Kronos Bio: Clinical-stage oncology company focused on therapies for AML and other hematologic cancers, with a pipeline of targeted agents. Highly comparable in therapeutic focus, stage, and indication to OncoVerity.
- Syndax Pharmaceuticals: Clinical-stage oncology biotech developing revumenib (a menin inhibitor) and other targeted therapies for AML. Direct competitor to OncoVerity in the elderly newly diagnosed AML space, pursuing combination strategies with venetoclax and azacitidine.
- Jazz Pharmaceuticals: Specialty biopharmaceutical company with an established AML franchise including Vyxeos (CPX-351) for secondary AML. Comparable as a focused hematology/oncology company with both commercial products and development pipeline in AML.
- argenx: Licensor of cusatuzumab and a board-level partner with two seats at OncoVerity. Comparable as a clinical-to-commercial antibody therapeutics company with a track record of out-licensing and developing innovative biologics for serious diseases.
Broad incumbents
- Roche: Through Genentech, co-develops venetoclax (Venclexta) — the backbone of OncoVerity's cusatuzumab combination regimen. As the established AML standard-of-care provider, Roche is both a combination partner and a potential competitive threat in the elderly AML market.
- AbbVie: Co-markets venetoclax (Venclexta) with Roche for AML. As a broad oncology incumbent with a major franchise in the venetoclax + azacitidine AML combination, AbbVie is both a partner context and the leading competitive benchmark for any cusatuzumab combination outcome.
- Bristol-Myers Squibb: Major oncology incumbent with multiple hematology products and a deep development pipeline in AML and related hematologic malignancies. Comparable as a strategic competitor and potential future partner or acquirer for OncoVerity's cusatuzumab program.
- Servier: International pharmaceutical company with a meaningful AML franchise including Tibsovo (ivosidenib) for IDH1-mutated AML. Comparable as a competing AML drug developer and marketer with established combination strategies in the elderly AML space.
Emerging players
- Notable Labs: Precision medicine platform company using functional drug screening and AI to identify effective AML therapies for individual patients. Comparable to OncoVerity in using computational tools for AML patient stratification and treatment selection.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
OncoVerity social profiles
Digital presenceOncoVerity financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoVerity leadership team
Management profileNumber of profiles
Profiles18 records
OncoVerity funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoVerity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoVerity
What does OncoVerity do?
OncoVerity is a clinical-stage biotechnology company developing cusatuzumab, a high-affinity anti-CD70 monoclonal antibody, for the treatment of acute myeloid leukemia (AML) and other cancers. The company applies an advanced multi-omics bioinformatics platform to identify patient subgroups who may benefit from cusatuzumab combination therapy with azacitidine and venetoclax, particularly elderly AML patients ineligible for intensive chemotherapy. Its clinical programs include the Elevate, Culminate, and Risk Stratified Phase 2 studies.
Is OncoVerity a public or private company?
OncoVerity is a private company. It is classified as venture growth investor backed and is currently operating.
When was OncoVerity founded?
OncoVerity was founded in 2023. It employs 1 to 10 people.
Where is OncoVerity based?
OncoVerity is headquartered in Aurora, United States, in the North America region.
How does OncoVerity make money?
One revenue line is on record: drug Development and Commercialization.
Who are OncoVerity's main competitors?
Direct peers on record are Aptose Biosciences, Kronos Bio, Syndax Pharmaceuticals, Jazz Pharmaceuticals and argenx. Broad incumbents are Roche, AbbVie, Bristol-Myers Squibb and Servier. Notable Labs is listed as an emerging player.
Does OncoVerity have an API?
No public API is recorded for OncoVerity.
What industry is OncoVerity in?
OncoVerity's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 621511 and its SIC code is 2835.